Nakamura Takafumi, Peng Kah-Whye, Harvey Mary, Greiner Suzanne, Lorimer Ian A J, James Charles D, Russell Stephen J
Nat Biotechnol. 2005 Feb;23(2):209-14. doi: 10.1038/nbt1060. Epub 2005 Jan 30.
Live attenuated measles viruses of the Edmonston lineage (MV-Edm) have potent anti-tumor activity but are not entirely tumor-specific owing to widespread distribution of their native receptors, CD46 and SLAM. We have therefore developed a pseudoreceptor system that allows rescue and propagation of fully retargeted viruses displaying single-chain antibody fragments. Viruses retargeted to tumor-selective CD38, epidermal growth factor receptor (EGFR) or EGFR mutant vIII (EGFRvIII) efficiently entered cells through their respective targeted receptors in vitro and in vivo, but not through CD46 and SLAM. When administered intratumorally or intravenously to mice bearing human CD38 or EGFR-positive human tumor xenografts, the targeted viruses demonstrated specific receptor-mediated anti-tumor activity. These data provide an in vivo demonstration of antibody-directed tumor destruction by retargeted oncolytic viruses.
埃德蒙斯顿谱系的减毒活麻疹病毒(MV-Edm)具有强大的抗肿瘤活性,但由于其天然受体CD46和信号淋巴细胞激活分子(SLAM)广泛分布,并非完全具有肿瘤特异性。因此,我们开发了一种假受体系统,该系统可实现展示单链抗体片段的完全重新靶向病毒的拯救和增殖。重新靶向肿瘤选择性的CD38、表皮生长因子受体(EGFR)或EGFR突变体vIII(EGFRvIII)的病毒在体外和体内均能通过各自的靶向受体有效进入细胞,但不会通过CD46和SLAM进入细胞。当将这些靶向病毒瘤内或静脉注射给携带人CD38或EGFR阳性人肿瘤异种移植瘤的小鼠时,它们表现出特异性受体介导的抗肿瘤活性。这些数据提供了重新靶向的溶瘤病毒通过抗体介导实现肿瘤破坏的体内证据。